Evolution of definitions of response, progression-free survival and event-free survival in front-line studies of chronic myeloid leukemia

被引:1
|
作者
Ansstas, George [1 ]
Vij, Ravi [1 ]
机构
[1] Washington Univ, Sch Med, Sect Bone Marrow Transplant & Leukemia, St Louis, MO 63110 USA
关键词
Chronic myeloid leukemia; chronic myelogenous leukemia; progression-free survival; event-free survival; disease progression; BCR-ABL inhibitor; DIAGNOSED CHRONIC-PHASE; COMPLETE CYTOGENETIC RESPONSE; CHRONIC MYELOGENOUS LEUKEMIA; KINASE INHIBITOR THERAPY; ALPHA PLUS CYTARABINE; MOLECULAR RESPONSES; FOLLOW-UP; IMATINIB; INTERFERON; DASATINIB;
D O I
10.3109/10428194.2011.653786
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Standardized definitions of response and outcome are useful to evaluate study data, facilitate treatment guideline adherence and aid clinical decision-making. Although definitions of response in chronic myeloid leukemia (CML) have been standardized, definitions of disease progression have not been standardized, despite widespread adoption of the term to reflect development of advanced disease. This article reviews definitions of response and disease progression used for progression-free survival and event-free survival in key CML studies and implications for interpreting patient response. It is proposed that adherence to definitions of progression from the European LeukmiaNet may aid future research and therapeutic decision-making.
引用
收藏
页码:1273 / 1281
页数:9
相关论文
共 50 条
  • [21] Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy
    Kohei Shitara
    Keitaro Matsuo
    Kei Muro
    Toshihiko Doi
    Atsushi Ohtsu
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1383 - 1389
  • [22] EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate
    Uz, Burak
    Buyukasik, Yahya
    Atay, Hilmi
    Kelkitli, Engin
    Turgut, Mehmet
    Bektas, Ozlen
    Eliacik, Eylem
    Isik, Ayse
    Aksu, Salih
    Goker, Hakan
    Sayinalp, Nilgun
    Ozcebe, Osman I.
    Haznedaroglu, Ibrahim C.
    HEMATOLOGY, 2013, 18 (05) : 247 - 252
  • [23] Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia
    Yanmin Zhao
    Jiasheng Wang
    Yi Luo
    Jimin Shi
    Weiyan Zheng
    Yamin Tan
    Zhen Cai
    He Huang
    Annals of Hematology, 2017, 96 : 1353 - 1360
  • [24] Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia
    Zhao, Yanmin
    Wang, Jiasheng
    Luo, Yi
    Shi, Jimin
    Zheng, Weiyan
    Tan, Yamin
    Cai, Zhen
    Huang, He
    ANNALS OF HEMATOLOGY, 2017, 96 (08) : 1353 - 1360
  • [25] Long-term progression-free survival in patients with chronic lymphocytic leukemia treated with novel agents: An analysis based on indirect comparisons
    Messori, Andrea
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (01) : 60 - 66
  • [26] Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis
    Howlett, Christina
    Snedecor, Sonya J.
    Landsburg, Daniel J.
    Svoboda, Jakub
    Chong, Elise A.
    Schuster, Stephen J.
    Nasta, Sunita Dwivedy
    Feldman, Tatyana
    Rago, Allison
    Walsh, Kristy M.
    Weber, Scott
    Goy, Andre
    Mato, Anthony
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (04) : 504 - 514
  • [27] Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan
    Liu, Hsi-Che
    Kuo, Ming-Chung
    Wu, Kang-Hsi
    Chen, Tsai-Yun
    Chen, Jiann-Shiuh
    Wang, Ming-Chung
    Lin, Tung-Liang
    Yang, YoungSen
    Ma, Ming-Chun
    Wang, Po-Nan
    Sheen, Jiunn-Ming
    Wang, Shih-Chung
    Chen, Shih-Hsiang
    Jaing, Tang-Her
    Cheng, Chao-Neng
    Yeh, Ting-Chi
    Lin, Tung-Huei
    Shih, Lee-Yung
    BRITISH JOURNAL OF CANCER, 2023, 128 (07) : 1294 - 1300
  • [28] Circulating Tumor Cells in Metastatic Breast Cancer: Monitoring Response to Chemotherapy and Predicting Progression-Free Survival
    Cheng, Jian-ping
    Yan, Ying
    Wang, Xiang-yi
    Lu, Yuan-li
    Yuan, Yan-hua
    Wang, Xiao-li
    Jia, Jun
    Ren, Jun
    CHINESE JOURNAL OF CANCER RESEARCH, 2010, 22 (03) : 201 - 210
  • [29] Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
    Imai, Hisao
    Mori, Keita
    Wakuda, Kazushige
    Ono, Akira
    Akamatsu, Hiroaki
    Shukuya, Takehito
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Kaira, Kyoichi
    Murakami, Haruyasu
    Endo, Masahiro
    Nakajima, Takashi
    Yamamoto, Nobuyuki
    Takahashi, Toshiaki
    ANNALS OF THORACIC MEDICINE, 2015, 10 (01) : 61 - 66
  • [30] Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival
    Simone De Leo
    Marta Di Stefano
    Luca Persani
    Laura Fugazzola
    Carla Colombo
    Endocrine, 2021, 72 : 462 - 469